Skip to content Skip to footer
Subscribe Now

NEWS

iCAD
RadNet to Acquire iCAD for ~$103M
Shots: RadNet has entered into a definitive merger agreement to acquire iCAD in an all-stock transaction, through which iCAD will become a wholly owned subsidiary of RadNet As per the deal, iCAD stockholders will receive 0.0677 RadNet shares/ iCAD share, representing transaction value of ~$103M, or ~$3.61/share (~98% premium) on a fully diluted basis; closing…
April 16, 2025
Eisai, Biogen and BioArctic
Eisai, Biogen and BioArctic Report the EC’s Approval of Leqembi (lecanemab) for Early Alzheimer’s Disease
Shots: The EC has approved Leqembi for the treatment of early Alzheimer’s disease in all 30 EEA states Eisai handles global development & regulatory filings for Leqembi, co-commercializing & co-promoting it with Biogen while retaining final decision-making authority. Eisai co-promotes Leqembi with Biogen in the EU (excl. Nordics) & with BioArctic in the Nordic countries, distributing it…
April 16, 2025
Zoetis
The US FDA Approves Zoetis’ Simparica Trio to Prevent Flea Tapeworm Infections in Dogs
Shots: The US FDA has approved label expansion of Simparica Trio to protect dogs against Dipylidium caninum (flea tapeworm) infections by killing Ctenocephalides felis vector fleas Simparica Trio (sarolaner, moxidectin, & pyrantel) is a parasiticide that protects dogs against heartworm disease, 6 tick species (incl. Lyme-transmitting deer ticks), fleas, roundworms, hookworms, & flea tapeworms Simparica…
April 16, 2025
Merck & Cyprumed
Merck Signs a ~$493M Deal with Cyprumed to Develop Oral Peptide Therapeutics
Shots: Cyprumed & Merck have entered into a non-exclusive license & option agreement to develop oral formulations of Merck’s peptides, leveraging Cyprumed’s innovative drug delivery tech  As per the deal, Merck has secured non-exclusive global rights to Cyprumed’s oral peptide delivery platform for an undisclosed number of targets, with an option to exclusively license it…
April 15, 2025
Bruno Vision Care
Bruno Vision Care’s Deseyne Contact Lens Secures the US FDA’s Approval for Dry Eye Disease
Shots: The US FDA has approved Deseyne (vifilcon C) daily disposable contact lens with FusionTechnology; commercially available in Q4’25 Deseyne lenses integrates 2 patented innovations: vifilcon C hydrogel material & FusionTechnology, to gradually release embedded Lachryceuticals (incl. amino acids, vitamins, & polysaccharides), ensuring sustained bioavailability & long-lasting eye comfort FusionTechnology combines hyaluronic acid & tamarind…
April 15, 2025
Cue Biopharma & Boehringer Ingelheim
Cue Biopharma Collaborates with Boehringer Ingelheim to Develop B cell-Targeting Bispecifics for Autoimmune and Inflammatory Diseases
Shots: BI & Cue Biopharma have entered into a multi-year strategic research & license agreement to develop & commercialize CUE-501 for autoimmune diseases, with the potential to expand into other B cell-targeting bispecifics using Cue’s Immuno-STAT platform As per the deal, Cue Biopharma will receive a $12M upfront & ~$345M in research, development, & commercial…
April 15, 2025
Load more